Abstract: Disclosed are a phthalic hydrazide (phthalazine ketone) compound, and a pharmaceutical composition comprising the same. As a DNA repair enzyme poly (ADP-ribozyme) polymerase inhibitor, the compound and the pharmaceutical composition can effectively treat diseases involving PARP enzymatic activity, including cancer, neural degenerative diseases, inflammation and the like.
Type:
Grant
Filed:
August 13, 2015
Date of Patent:
August 1, 2017
Assignee:
CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD.
Inventors:
Jianxin Ji, Na Guo, Ting Xue, Bingqiang Kang, Xinfa Ye, Xin Chen, Tao Zhang
Abstract: Disclosed are a phthalic hydrazide (phthalazine ketone) compound, and a pharmaceutical composition comprising the same. As a DNA repair enzyme poly (ADP-ribozyme) polymerase inhibitor, the compound and the pharmaceutical composition can effectively treat diseases involving PARP enzymatic activity, including cancer, neural degenerative diseases, inflammation and the like.
Type:
Grant
Filed:
December 3, 2012
Date of Patent:
November 17, 2015
Assignee:
CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD.
Inventors:
Jianxin Ji, Na Guo, Ting Xue, Bingqiang Kang, Xinfa Ye, Xin Chen, Tao Zhang
Abstract: Disclosed are a phthalic hydrazide (phthalazine ketone) compound, and a pharmaceutical composition comprising the same. As a DNA repair enzyme poly (ADP-ribozyme) polymerase inhibitor, the compound and the pharmaceutical composition can effectively treat diseases involving PARP enzymatic activity, including cancer, neural degenerative diseases, inflammation and the like.
Type:
Application
Filed:
December 3, 2012
Publication date:
February 19, 2015
Applicant:
CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD.
Inventors:
Jianxin Ji, Na Guo, Ting Xue, Bingqiang Kang, Xinfa Ye, Xin Chen, Tao Zhang
Abstract: Disclosed is a synthesis method of a compound of formula 1,5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxyl]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one (i.e. aprepitant), which comprises cyclizing a compound of formula 4 in a solvent, wherein R is C1-C5 alkyl. The intermediate for preparing aprepitant is also disclosed. The present method is especially suitable for industrial production of aprepitant.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
January 27, 2015
Assignee:
Chengdu DI'AO Pharmaceutical Group Co., Ltd.
Inventors:
Jianxin Ji, Qiang Zhang, Fengtian Du, Yi Jin, Tao Zhang, Na Guo, Xiaowei Yan, Yongrongn Yang, Bogang Li
Abstract: The present invention provides a pharmaceutical composition containing steroidal saponins. The pharmaceutical composition comprises 5˜25 parts by weight of furostanal saponins represented by general formula A or general formula B and 1˜10 parts by weight of spirostanol saponin represented by general formula C. The present invention further provides a method for preparing the pharmaceutical composition. After determination of the three steroidal saponin components in the pharmaceutical composition of the present invention, it is proved that it has high stability and liability in its therapeutic effect. Meanwhile, the method to identify the three steroidal saponins is provided with reliable controllability. Besides, with its daily dosage of 300˜600 mg, which is less dosage, the drug of this invention provides a new choice in clinics.
Type:
Application
Filed:
September 29, 2005
Publication date:
November 1, 2007
Applicant:
CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD.